Followers | 53 |
Posts | 3489 |
Boards Moderated | 0 |
Alias Born | 02/05/2014 |
Thursday, March 05, 2015 3:49:31 PM
However, as I recently pointed out, DNA management likely can only get funding for their new product by selling new shares into the market. Yup, that means dilution. As long as the dilution gets the company another roll of the dice in the marketplace with a new product, I am happy and have no problem supporting the company's actions.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM